Rhinitis, Allergic, Seasonal Clinical Trial
Official title:
A Multi-national, Randomised, DBPC, Phase II Study to Assess the Efficacy and Safety of Three Doses of SLIT Administered as rBet v 1 Tablets Once Daily to Patients Suffering From Birch Pollen Rhinoconjunctivitis
The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.
Status | Completed |
Enrollment | 483 |
Est. completion date | August 2009 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Symptomatic birch pollen-related allergic rhinoconjunctivitis for at least the last 2 pollen seasons - Sensitisation to birch pollen as demonstrated, at screening, by a positive SPT to birch pollen with wheal diameter greater than 3 mm and specific IgE levels > 0.70 kU/L (birch pollen and rBet v 1) - Patients asymptomatic to all other allergens during the birch pollen season - RRTSS during the previous pollen season = 12 out of a maximum possible score of 18 - Patients with an FEV1 = 80% of the predicted value - Female patients with no childbearing potential - Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method and have a negative urine pregnancy test, and are willing and able to sign written informed consent stating that they will use appropriate contraception and not plan a pregnancy during this study - Patients able to be compliant with respect to the completion of the daily record card and taking of the investigational products - Patients having provided signed informed consent Exclusion Criteria: - Patients with symptoms of rhinoconjunctivitis during the birch pollen season due to non-birch-related allergens - Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to house dust mites - Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to cat or dog allergens, and living with these animals at home or at risk of frequent contacts with these animals (family, friends etc.) during the course of the study - Patients who previously received desensitisation treatment to birch pollen and/or another Betulaceae sp. within the previous 10 years - Patients with asthma (except birch seasonal asthma in which case the patient could be included in the study) - Patients with any nasal or oral condition that could interfere with efficacy or safety assessments (such as nasal polyposis or oral inflammation) - Patients with a past or current disease, which as judged by the investigator, may affect the patient's participation in or outcome of this study - Any disease or condition which would place a patient at undue risk by being included in the study (according to the investigator's opinion) - Usual contra-indications of immunotherapy such as concomitant local or systemic beta-blocker therapy and/or immunosuppressive drugs - Patients with ongoing treatment by immunotherapy with another allergen - Patients treated with inhaled/systemic steroids within 4 weeks prior to Screening, or with long acting systemic corticosteroids 12 weeks before Screening - Patients under continuous corticotherapy or undergoing chronic treatment with H2-antihistamine drugs - Known hypersensitivity to mannitol - Pregnancy, breast-feeding/lactation or sexually active women of childbearing potential who are not using a medically accepted contraceptive method - Patients with a history of drug or alcohol abuse |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | National University Hospital - Allergy Unit 4222 | Copenhagen | |
Finland | Helsingin yliopistollinen keskussairaala | Helsinki | |
France | NHC, Hôpitaux Universitaires de Strasbourg | Strasbourg | |
Germany | Charité universitaetsmedizin | Berlin | |
Lithuania | Public Institution Kaunas Medical University Hospital | Kaunas | |
Poland | SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Lodzi | Lodz | |
Russian Federation | Institute of Immunology of FMBA | Moscow | |
Sweden | Sabina RAK | Gothenburg |
Lead Sponsor | Collaborator |
---|---|
Stallergenes | Aptuit Inc., Quintiles, Inc. |
Denmark, Finland, France, Germany, Lithuania, Poland, Russian Federation, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average Adjusted Symptom Score | ~1 month (whole birch pollen season) | No | |
Secondary | Average Rhinoconjunctivitis Total symptom Score | ~1 month (whole birch pollen season) | No | |
Secondary | Rescue Medication Score | ~1 month (whole birch pollen season) | No | |
Secondary | Average Combined Score | ~1 month (whole birch pollen season) | No | |
Secondary | Proportion of symptom-controlled days | ~1 month (whole birch pollen season) | No | |
Secondary | Global evaluation by the patient | after 5-6 months of treatment | No | |
Secondary | Immunological markers (IgE and IgG4) | 6-7 months | No | |
Secondary | Sensitisation status | At least 6 months | No | |
Secondary | Lower airways symptoms | ~1 month (whole birch pollen season) | No | |
Secondary | Safety assessments | 6-7 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01337323 -
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting
|
N/A | |
Completed |
NCT00851344 -
Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo
|
Phase 2 | |
Completed |
NCT00537355 -
An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber
|
Phase 2 | |
Completed |
NCT00501527 -
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
|
Phase 2 | |
Completed |
NCT00422149 -
Twin SUBLIVAC® Grasses Clinical Efficacy Study
|
Phase 3 | |
Completed |
NCT00542607 -
Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00605852 -
Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Completed |
NCT02256553 -
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
|
Phase 4 | |
Completed |
NCT01007721 -
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season
|
Phase 2 | |
Completed |
NCT00932256 -
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients
|
Phase 1 | |
Completed |
NCT00384475 -
A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)
|
Phase 3 | |
Completed |
NCT00839189 -
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
|
Phase 1 | |
Completed |
NCT00135629 -
Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever
|
Phase 3 | |
Completed |
NCT04687059 -
An Exploratory Study of PQ Grass 27600 SU
|
Phase 2/Phase 3 | |
Completed |
NCT00889460 -
Safety and Tolerability Study of rBet v1 SLIT Tablets
|
Phase 1 | |
Completed |
NCT00396149 -
Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1
|
Phase 1 | |
Completed |
NCT00659594 -
Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)
|
Phase 3 | |
Completed |
NCT00127647 -
An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)
|
Phase 3 | |
Completed |
NCT01480271 -
An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.
|
Phase 1 |